Yes. This multi-active compounded topical preparation is available only pursuant to a valid prescription from a licensed healthcare provider. A telehealth consultation, comprehensive hair loss evaluation, and complete medication and health history review are required before dispensing. Given the complexity of this four-active formulation, thorough provider evaluation and detailed patient counseling regarding each ingredient are essential before initiating treatment.

Each active ingredient contributes distinct side effect considerations that are reviewed individually during your consultation. Minoxidil may cause initial shedding (4 to 8 weeks), scalp irritation, and occasional cardiovascular effects with significant systemic absorption. Tretinoin's penetration-enhancing properties increase absorption of co-actives and may cause scalp sensitivity, redness, or dryness. Progesterone has hormonal activity and systemic absorption potential, which is relevant in certain patient populations. Finasteride carries a risk of sexual side effects even at topical doses, and is teratogenic — women of childbearing potential must not use or handle this formulation. The combined profile of four actives requires close provider monitoring during the initial treatment phase.

Women who are pregnant or may become pregnant must not use or handle this formulation — finasteride is teratogenic. Patients with a history of hormone-sensitive malignancy, significant hepatic impairment, or hypersensitivity to any component must not use this preparation without thorough provider and oncological evaluation. Active scalp conditions must be resolved before initiating treatment. This is the most complex formulation in the hair restoration line and requires the most thorough provider review of any concurrent medications or health conditions before prescribing.

This formulation carries four distinct interaction profiles. Finasteride interacts with CYP3A4 modulators. Minoxidil may have additive antihypertensive effects. Progesterone interacts with systemic hormone therapies, anticoagulants, and potassium-sparing agents. Tretinoin's penetration-enhancing activity may increase absorption of other topicals applied concurrently. Patients on anticoagulants, antihypertensives, hormonal therapies, or any CYP3A4-modulating medications should discuss all concurrent agents with their provider before beginning treatment.

The complexity of this four-active formulation means thorough provider assessment is essential for anyone with cardiovascular disease, hepatic conditions, hormonal disorders (including PCOS or thyroid disease), or a history of any malignancy. Regular laboratory monitoring and provider follow-up during treatment are standard of care. Your provider will carefully evaluate your complete health history before prescribing and will determine the appropriate starting protocol and monitoring schedule for your individual situation.